You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

24 search results for: CRSwNP

<b>CRSwNP</b>: A Chronic Type 2 Inflammatory Disease

expert video

CRSwNP: A Chronic Type 2 Inflammatory Disease

2 min

Rhinology

Prof. Peter Hellings describes how type 2 inflammation drives CRSwNP.

How do You Define Active Disease (<b>CRSwNP</b>) When Looking at the Nose With an Endoscope?

expert video

How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?

2 min

Rhinology

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.

What proportion of patients can achieve control in <b>CRSwNP</b>?

expert video

What proportion of patients can achieve control in CRSwNP?

5 min

Rhinology

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.

expert video

Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?

5 min

Rhinology

Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.

Connecting Type 2 Inflammation to <b>CRSwNP</b>

expert video

Connecting Type 2 Inflammation to CRSwNP

1 min

Rhinology

Prof. Claus Bachert describes how type 2 inflammation drives CRSwNP.

Defining Mechanisms of Anosmia in <b>CRSwNP</b>

expert video

Defining Mechanisms of Anosmia in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens examines what is known and what else should be explored to understand the mechanisms of anosmia in patients with CRSwNP.

<b>CRSwNP</b> Significantly Affects the Quality of Life of <b>CRSwNP</b> Patients

interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

10 min

Rhinology

Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.

expert video

Should we Still Operate on Patients With Chronic Rhinosinusitis With Nasal Polyps?

2 min

Rhinology

This video clip from the EAACI 2024 symposium discusses whether patients with CRSwNP should undergo a surgery.

Importance of Endotyping in <b>CRSwNP</b>

expert video

Importance of Endotyping in CRSwNP

2 min

Rhinology

Prof. Wytske Fokkens discusses the role of endotyping in the management of CRSwNP.

The Pathophysiology of Type 2 Inflammation in <b>CRSwNP</b>

interactivity

The Pathophysiology of Type 2 Inflammation in CRSwNP

5 min

Rhinology

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP

Why did the definition of control in <b>CRSwNP</b> change between EPOS 2020 and EPOS/EUFOREA 2024?

expert video

Why did the definition of control in CRSwNP change between EPOS 2020 and EPOS/EUFOREA 2024?

5 min

Rhinology

Prof. Hellings and Prof. Corso discuss the significance and rationale behind the new definition of CRSwNP.

expert video

ERS-ISIAN 2023 | From Endotype to Phenotype: Linking Pathophysiology to Burden and Clinical Management for Patients with Uncontrolled and/or Severe CRSwNP

9 min

Rhinology

Prof. Peter Hellings discusses the interconnection between the pathophysiology, burden and clinical management of uncontrolled and/or severe CRSwNP

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ItalyChange country/region